Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Lutetium Lu 177 vipivotide tetraxetan by Advanced Accelerator Applications for Castration-Resistant Prostate Cancer (CRPC): Likelihood of Approval
Lutetium Lu 177 vipivotide tetraxetan is under clinical development by Advanced Accelerator Applications and currently in Phase II for Castration-Resistant...
Lutetium Lu 177 vipivotide tetraxetan by Advanced Accelerator Applications for Hormone-Sensitive Prostate Cancer: Likelihood of Approval
Lutetium Lu 177 vipivotide tetraxetan is under clinical development by Advanced Accelerator Applications and currently in Phase III for Hormone-Sensitive...
Lutetium Lu 177 vipivotide tetraxetan by Advanced Accelerator Applications for Metastatic Prostate Cancer: Likelihood of Approval
Lutetium Lu 177 vipivotide tetraxetan is under clinical development by Advanced Accelerator Applications and currently in Phase III for Metastatic...